

1-1-2023

Bacterial pneumonia associated with multidrug-resistant Gram-negative pathogens: Understanding epidemiology, resistance patterns, and implications with COVID-19

Dalal Hammoudi Halat
Qatar University

Carole Ayoub Moubareck
Zayed University

Follow this and additional works at: <https://zuscholars.zu.ac.ae/works>



Part of the [Life Sciences Commons](#)

Recommended Citation


Hammoudi Halat, Dalal and Ayoub Moubareck, Carole, "Bacterial pneumonia associated with multidrug-resistant Gram-negative pathogens: Understanding epidemiology, resistance patterns, and implications with COVID-19" (2023). *All Works*. 5792.
<https://zuscholars.zu.ac.ae/works/5792>

This Article is brought to you for free and open access by ZU Scholars. It has been accepted for inclusion in All Works by an authorized administrator of ZU Scholars. For more information, please contact scholars@zu.ac.ae.



REVIEW

Bacterial pneumonia associated with multidrug-resistant Gram-negative pathogens: Understanding epidemiology, resistance patterns, and implications with COVID-19 [version 1; peer review: 1 approved with reservations]

Dalal Hammoudi Halat ^{1,2}, Carole Ayoub Moubareck³

¹QU Health, Qatar University, Doha, Qatar

²Department of Pharmaceutical Sciences, Lebanese International University, Bekaa, Lebanon

³College of Natural and Health Sciences, Zayed University, Dubai, United Arab Emirates

V1 First published: 24 Jan 2023, 12:92
<https://doi.org/10.12688/f1000research.129080.1>
Latest published: 24 Jan 2023, 12:92
<https://doi.org/10.12688/f1000research.129080.1>

Abstract

The ongoing spread of antimicrobial resistance has complicated the treatment of bacterial hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Gram-negative pathogens, especially those with multidrug-resistant profiles, including *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter* spp., *Pseudomonas aeruginosa*, and *Acinetobacter* spp., are an important culprit in this type of infections. Understanding the determinants of resistance in pathogens causing pneumonia is ultimately stressing, especially in the shadows of the COVID-19 pandemic, when bacterial lung infections are considered a top priority that has become urgent to revise. Globally, the increasing prevalence of these pathogens in respiratory samples represents a significant infection challenge, with major limitations of treatment options and poor clinical outcomes. This review will focus on the epidemiology of HAP and VAP and will present the roles and the antimicrobial resistance patterns of implicated multidrug-resistant (MDR) Gram-negative pathogens like carbapenem-resistant *Acinetobacter baumannii* (CRAB), carbapenem-resistant *Pseudomonas aeruginosa* (CRPA), carbapenem-resistant *Enterobacterales* (CRE), as well as colistin-resistant Gram-negative pathogens and extended-spectrum β -lactamase (ESBL)-producing *Enterobacterales*. While emerging from the COVID-19 pandemic, perspectives and conclusions are drawn from findings of HAP and VAP caused by MDR Gram-negative bacteria in patients with COVID-19.

Keywords

hospital-acquired pneumonia; ventilator-associated pneumonia; antimicrobial resistance; Gram-negative multi-drug resistant pathogens.

Open Peer Review


Approval Status ?

1

version 1

24 Jan 2023

?
view

1. **Ghassan Dbaibo** , American University of Beirut Medical Center, Beirut, Lebanon

Any reports and responses or comments on the article can be found at the end of the article.



This article is included in the **Pathogens** gateway.



This article is included in the **Antimicrobial Resistance** collection.

Corresponding author: Dalal Hammoudi Halat (dalal.hammoudi@liu.edu.lb)

Author roles: **Hammoudi Halat D:** Data Curation, Funding Acquisition, Resources, Visualization, Writing – Original Draft Preparation; **Ayoub Moubareck C:** Conceptualization, Data Curation, Project Administration, Supervision, Visualization, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was funded by the Lebanese International University under the reference number PHAR-DH-JOUR-001-2023.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2023 Hammoudi Halat D and Ayoub Moubareck C. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Hammoudi Halat D and Ayoub Moubareck C. **Bacterial pneumonia associated with multidrug-resistant Gram-negative pathogens: Understanding epidemiology, resistance patterns, and implications with COVID-19 [version 1; peer review: 1 approved with reservations]** F1000Research 2023, 12:92 <https://doi.org/10.12688/f1000research.129080.1>

First published: 24 Jan 2023, 12:92 <https://doi.org/10.12688/f1000research.129080.1>

Introduction

Originating from the ancient Greek “pneumon”, or lung, pneumonia is defined as inflammation of the parenchyma of either one or both lungs, which is usually, but not always, caused by infection, and remains a foremost cause of hospitalization among both adults and children,¹ with a hospitalization rate close to 400 per 100 000 population in the United States² and over seven million hospitalizations per year worldwide.³ Pneumonia has to be considered in patients with acute onset of fever, chills, cough, dyspnea, fatigue, purulent sputum, anorexia, and pleuritic chest pain.⁴ Pneumonia represents the eighth most expensive condition for hospitalization, with an estimated total cost exceeding USD 9.5 billion per year in US hospitals.⁵

Although a causative pathogen may stay unrecognized, bacteria, viruses, fungi, and parasites may be implicated in pneumonia.⁶ While viruses like influenza A and B, coronaviruses, rhinoviruses, respiratory syncytial viruses, parainfluenza viruses, and others, are very frequent pathogens in pneumonia,^{6–8} bacterial pneumonia continues to be one of the most serious public health problems due to its medical and economic burden.⁹

According to the American Thoracic Society,¹⁰ pneumonia can be classified into community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), and ventilator associated pneumonia (VAP). While any pneumonia acquired outside the hospital or in community settings may be considered as CAP, HAP is defined as a pneumonia occurring 48 hours or more after hospital admission, and which was not incubating at the time of admission. On the other hand, VAP refers to pneumonia occurring more than 48–72 hours after endotracheal intubation.^{10,11} As of 2016, the term “healthcare-associated pneumonia” (HCAP) is no longer recognized in medical literature. This category of pneumonia was referred to cases acquired in healthcare facilities including nursing homes, hemodialysis centers, and outpatient clinics, or during hospitalization within the past 90 days.¹¹ HCAP was a condition used to identify patients at risk of pneumonia caused by multidrug-resistant (MDR) pathogens depending upon specific risk factors and illness severity. However, this categorization appeared to be excessively sensitive and may have led to increased, inappropriate, broad-spectrum antibiotic use. Although patients having recent contact with healthcare facilities were at a higher risk for infection with such MDR pathogens, this risk remained small for most patients and the overall incidence of these pathogens was low, since it did not exceed 7% in high quality studies, and did not directly relate to patient mortality.^{12–14} Accordingly, purposeful removal of the category of HCAP was done in 2016, and it was not classified as a discrete type of pneumonia in the 2017 guidelines on the management of HAP and VAP from Europe and Latin America.¹⁵

Despite the availability of guidelines for management of HAP and VAP,¹⁶ and the growing trend in understanding these infections, successful treatment remains complex to achieve,¹⁷ and the incidence does not seem to be decreasing.¹⁸ In this review, both the epidemiological and microbiological properties of HAP and VAP shall be highlighted, with focus on implicated Gram-negative MDR pathogens and their resistance patterns. Finally, and in the light of COVID-19, the importance of these pathogens in HAP and VAP shall be discussed according to relevant literature reporting them in the wake of the global pandemic.

Risk factors and epidemiology of HAP and VAP

HAP and VAP represent some of the most common and serious infections occurring in hospitalized patients,¹⁹ and remain important causes of morbidity and mortality despite advances in antimicrobial therapy, numerous supportive care modalities, and the use of a wide-range of preventive measures.^{11,18} Although the Centers for Disease Control and Prevention (CDC) estimate that over two-thirds of HAP in the United States occur in non-ventilated patients, there is a major gap in research on HAP, as most hospitals routinely track VAP, and most of the knowledge we have about nosocomial pneumonia including incidence, risk factors, mortality and prevention come from ventilated patients.²⁰ The most significant risk factors for HAP are old age²¹ and comorbidities including coronary heart disease, diabetes, chronic lung disease, chronic renal failure, and thyroid disorders.^{22,23} Mechanical ventilation,²⁴ especially if prolonged for more than two weeks,²¹ reintubation or tracheostomy,²⁵ major chest or abdominal surgery,²⁶ as well as previous antibiotic exposure, especially to broad-spectrum antibiotics,²⁷ are possible risk factors for VAP. Of note, some studies have reported an increased incidence of HAP when the gastric pH is increased with the use of medications including H₂ receptor blockers, antacids, or proton pump inhibitors.^{28,29}

HAP remains a highly prevalent and morbid hospital-acquired infection, second only to nosocomial bloodstream infections,³⁰ and its incidence ranges from 5–20 cases per 1000 hospital admissions, with highest rates observed among immunocompromised, surgical and elderly patients.³¹ It is reported to affect nearly 0.5 to 1.7% of all hospitalized patients, and to be the leading cause of mortality among all hospital-acquired infections.⁹ HAP frequently causes prolonged hospital stay, increased antimicrobial usage, and additional cost of treatment.³²

VAP is the most prevalent nosocomial infection in the intensive care unit (ICU), where it constitutes about 25% of ICU infections.³³ About 10% of patients on mechanical ventilation may develop VAP.³⁴ Moreover, according to results of

meta-analysis, the attributable mortality rate in VAP was higher for surgical patients and those with severe illness at the time of admission.³⁵ Patients with VAP usually have a longer hospital course and excess mortality, and invite higher healthcare costs than similarly ill patients but without VAP.¹⁶

Among ICU patients, both HAP and VAP are associated with high morbidity and mortality rates, since these patients are already weak and critically ill. The estimated all-cause mortality in such patients is between 25-50%. Globally, HAP and VAP are considered the leading causes of death due to hospital-acquired infection, with an estimated global mortality of 20–30% due to HAP, and 20–50% due to VAP.³⁶ In a comparative analysis of longitudinal prospective studies, and in the ICU setting, HAP and VAP were responsible for 82% and a 38% rise in the risk of 30-day mortality respectively.³⁷ With the current standards of therapy, the clinical success rates for patients admitted to the ICU with HAP or VAP are often below 60%, and this may be explained by challenges of antibiotic therapy in critically ill patients, complexity of identifying microbial etiologies, relatively low penetration of most antibiotics into the lungs, as well as frequency of difficult-to-treat or highly resistant pathogens in that setting.³⁸

Microbiology of HAP and VAP: The role of MDR Gram-negative pathogens

Concise knowledge of the microbial etiologies of HAP and VAP allows better identification of patients at high risk of infection caused by problematic pathogens, such as MDR Gram-negative and extended spectrum beta-lactamase (ESBL)-producing *Enterobacteriales*, in addition to carbapenemase-producing Gram-negative bacteria. This should guide better selection of antibiotics and assessment of treatment protocols.³⁹ A persistent clinical dilemma regarding the causes of HAP and VAP resides in that detection of a microorganism from a respiratory tract sample does not necessarily indicate it as the causative agent of pneumonia.⁴⁰ HAP and VAP may be caused by a wide variety of pathogens and can be polymicrobial.

Evidence indicates that *Streptococcus pneumoniae*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Haemophilus influenzae*, *Pseudomonas aeruginosa*, *Moraxella catarrhalis*, and *Escherichia coli* were the most identified causes of typical pneumonia, while atypical pneumonia is mostly attributed to pathogens like *Legionella pneumophila*, *Chlamydia pneumoniae*, and *Mycoplasma pneumoniae*. Despite the fact that *S. pneumoniae* is the most important cause of CAP globally, Gram-negative bacteria are commonly related to HAP and VAP.⁹ In general, the implicated in HAP and VAP are *Staphylococcus aureus* (especially methicillin-resistant *S. aureus* (MRSA) strains), *Pseudomonas* species (especially *P. aeruginosa*), *Acinetobacter* species, *E. coli*, in addition to *Klebsiella* species (including extended-spectrum β-lactamase (ESBL)-producing and the extensively drug-resistant (XDR) *Enterobacteriales*). These pathogens account for nearly 80% of all episodes.^{41,42} Pneumonia etiology is thought to have shifted towards Gram-negative pathogens,⁹ and this may be perpetuated by overuse of existing antimicrobial agents, which has led to the development of adaptive resistance mechanisms by bacteria; lack of good antimicrobial stewardship resulting in increased resistance; and lack of adequate infection control practices.⁴³

The involvement of Gram-negative bacteria in HAP and VAP differs across studies in different world regions. In a systematic review and meta-analysis conducted on Asian countries, and among a sum of 14295 organisms identified in VAP, the most predominant culprit was *Acinetobacter baumannii* (26%), followed by *P. aeruginosa* (22%), *K. pneumoniae* (14%), and *S. aureus* (14%).⁴⁴ Similarly, in the Southeast Asian region, a part of the world with limited health resources and underestimation of infectious diseases, a comparison of causative agents of VAP among 24 different studies showed that *Acinetobacter* spp., followed by *P. aeruginosa*, and then *K. pneumoniae* were the commonest Gram-negative organisms implicated in the disease.⁴⁵

In European ICUs, and according to a prospective, multicenter, observational study on HAP and VAP, the most common isolates identified were *S. aureus*, with a prevalence of 16% for methicillin-sensitive and 16% for methicillin-resistant, *P. aeruginosa* (23%), and *A. baumannii* (19%).⁴⁶ In a large study enrolling patients with VAP from 27 ICUs in nine European countries, the dominant isolates were *S. aureus* in Spain, France, Belgium and Ireland, *P. aeruginosa* in Italy and Portugal, *Acinetobacter* in Greece and Turkey, and *E. coli* in Germany.⁴⁷ Other reports document the high prevalence of *Enterobacteriales* in nosocomial pneumonia, like a report from Poland⁴⁸ citing 42.0 % of *Enterobacteriales*, 37% of *A. baumannii*, 16% of *P. aeruginosa*, and 5% of *S. maltophilia*. In 2017, and in an investigation from Serbia on HAP and VAP causes, Gram-negative agents were mostly isolated; the most common pathogens were *Acinetobacter* spp. and *P. aeruginosa*, accounting for over 60% of isolates.⁴⁹ Similarly, in a 10-year surveillance study in a tertiary medical center in Lebanon on VAP causes, Gram-negative organisms were predominant among isolated pathogens (95%), with *A. baumannii* being the leading culprit (33%), followed by *P. aeruginosa* (17%) and *E. coli* (12%).⁵⁰ Parallel results were reported in Saudi Arabia in a 6-year analysis by El-Saed and Colleagues.⁵¹ In a study from the United Arab Emirates involving a 20-bedded, mixed, medical and surgical ICU, *K. pneumoniae* was the most prevalent organism (21%) in VAP, followed by *S. aureus* (16%), and *P. aeruginosa* (16%).⁵²

In the United States, and in an antimicrobial surveillance program in 2010 intended to establish the pathogens most likely to cause HAP or VAP, a consistent group of 6 organisms (*S. aureus* [28.0%], *P. aeruginosa* [21.8%], *Klebsiella* species [9.8%], *E. coli* [6.9%], *Acinetobacter* spp. [6.8%], and *Enterobacter* spp. [6.3%]) caused approximately 80% of HAP or VAP. Lower prevalence of *Serratia* species, *Stenotrophomonas maltophilia*, and community-acquired pathogens, such as pneumococci and *Haemophilus influenzae* were reported.⁵³ In 2016, a report by the Centers of Disease Control and Prevention (CDC)⁴¹ indicated a similar ranking in VAP for *S. aureus*, *P. aeruginosa*, and *Klebsiella* spp., followed by *Enterobacter* spp. and *E. coli*. The incidence was different in an investigation carried in the ICU on patients with HAP or VAP, with *S. maltophilia* being most prevalent (34%), followed by *P. aeruginosa* (40%), *A. baumannii* (32%), and *S. aureus* (28%).⁵⁴ As such, the etiological diagnosis of bacterial causes of HAP and VAP shows variable distribution of frequent pathogens, underlining the necessity for incessant, vigilant monitoring of these data across the continuum of HAP and VAP in different areas worldwide.

Resistance patterns of the important MDR Gram-negative bacteria implicated in HAP and VAP

The common MDR Gram-negative pathogens recognized for their role in HAP and VAP are *A. baumannii*, *P. aeruginosa*, and *K. pneumoniae*. Below, the roles and the antimicrobial resistance patterns of carbapenem-resistant *Acinetobacter baumannii* (CRAB), carbapenem-resistant *P. aeruginosa* (CRPA), carbapenem-resistant *Enterobacterales* (CRE), colistin-resistant Gram-negative pathogens, and extended-spectrum β -lactamase (ESBL)-producing *Enterobacterales*, in HAP and VAP are summarized, and presented in Figure 1. This is especially important in light of the World Health Organization (WHO) classification of some of these pathogens as critical priority bacteria and urgent threats that should be addressed appropriately.⁵⁵

Carbapenem-resistant *A. baumannii* (CRAB)

A. baumannii is an organism with extensive resistance to antimicrobial agents and with a profile perfectly compliant to healthcare settings, where it grows as cause of HAP and VAP.⁵⁶ Carbapenem resistance in *A. baumannii* is conveyed by several mechanisms acting in concert, including decrease in its outer membrane permeability, overactivity of efflux pumps, and increased production of cephalosporinases belonging to the AmpC group. However, the most predominant mechanism of carbapenem resistance in *A. baumannii* remains the production of carbapenemases of Ambler classes B and D.⁵⁷ Moreover, there are also reports of specific Ambler class A carbapenemases among *A. baumannii* strains.⁵⁸

The earliest case report of CRAB in nosocomial pneumonia was described in a mechanically ventilated patient in the ICU of a Spanish hospital in 1998.⁵⁹ Since then, an escalating trend of resistance among *A. baumannii* isolates has grown to




Figure 1. Incriminated Gram-negative bacteria in HAP and VAP.

become a concerning issue in clinical settings,⁴² and this organism appears endemic in countries of North Africa and the Middle East, and has caused several outbreaks in European countries as well.⁶⁰ The documentation of CRAB was not necessarily correlated with in-hospital mortality,⁶¹ but previous exposure to antibiotics and the severity of VAP were identified as risk factors for infection, and could be minimized by judicious use of carbapenems and colistin.⁶²

The rates of carbapenem resistance among *A. baumannii* in VAP and HAP is variable with some reports of 60%⁶³ and other studies with numbers as high as 86%.^{60,64} Drug-resistant *A. baumannii* in VAP is reported to confer longer hospital stays and increased mortality, which can exceed 60%.^{65,66} The length of hospital stay, previous antibiotic treatment, duration of mechanical ventilation, disease severity, and predominance of drug-resistant *A. baumannii* strains in hospital environments have been recognized as risk factors for VAP due to MDR *A. baumannii*.⁶² Plasmids of CRAB isolates that harbor genetic determinants coding for different carbapenem-hydrolysing class D β -lactamases (*bla*_{OXA-23}, *bla*_{OXA-58}, *bla*_{OXA-58-like}, and *bla*_{OXA-72}), result in high-level resistance to all carbapenems.⁴² For example, in Brazilian university hospitals, CRAB isolates with plasmids carrying OXA-23-encoding gene were identified in a range of about 70%⁶⁷ to 100%⁶⁸ of VAP cases. Likewise, 100% of *A. baumannii* strains identified in a study on VAP from Pakistan were CRAB, of which 95% positively amplified *bla*_{OXA-23} gene.⁶⁹ In China, a recent 7-year analysis of the molecular epidemiology of VAP showed that CRAB caused 65% of *A. baumannii* VAP cases, and carbapenem resistance was related to expression of OXA-23 and OXA-24, as well as efflux pump-encoding genes (AdeABC and AdeFGH). Infection with CRAB was significantly associated with longer mechanical ventilation time and longer antibiotic administration after VAP diagnosis.⁷⁰ Also in China, according to a retrospective analysis, CRAB-induced HAP occurred mostly in patients with underlying diseases, and those who received antimicrobial therapies including broad-spectrum β -lactams, invasive mechanical ventilation, and catheterization. The genes encoding OXA-23 were detectable in 97% of the strains.⁷¹ In Iran, as reported in an investigation of CRAB in VAP, resistance rates to both imipenem and meropenem were above 90%, and the frequencies of OXA-23 and OXA-24 were 58 and 31% respectively, with 42% of the strains harboring the insertion sequence *ISAbal* upstream of OXA carbapenemases capable of modulating their expression and transfer.⁷² In Vietnam, over 80% of *A. baumannii* strains from HAP were carbapenem-resistant with the carbapenemase genes *bla*_{OXA-23-like}, *bla*_{OXA-58-like}, and *bla*_{NDM-1}, with rates of 78, 10, and 6%, respectively.⁷³ The rates of carbapenem resistance in *A. baumannii* were as high as 97% in a VAP study involving three European countries, Greece, Spain, and Italy. Resistance was associated with an acquired carbapenemase, OXA-23 (80%), OXA-40 (5%), OXA-58 (2%) or OXA-23/58 (2%). Almost 65% of CRAB isolates were XDR or pandrug resistant, and belonged to a predominant clonal lineage, suggesting the presence of an epidemic clone and highlighting the difficulty in empirical treatment of CRAB.⁷⁴ The expansion of resistance in CRAB isolates and their increasing detection in nosocomial infections like HAP and VAP necessitate precise and regular programs of surveillance and control.

Carbapenem-resistant *P. aeruginosa* (CRPA)

Although a wide spectrum of bacteria can cause HAP and VAP, *P. aeruginosa* remains one of the most frequent causative pathogens.⁴¹ Multifaceted, opportunistic, and drug-resistant, *P. aeruginosa* continues to be a major source of infections in HAP and VAP with high morbidity and mortality. Its enormous potential for variation and the large number of virulence factors the pathogen has at its disposal allow it to be adaptable and flexible, giving it the opportunity to customize its response to healthcare settings where it lingers as a major concern.⁷⁵ In 2019, the CDC reported that *P. aeruginosa* has a carbapenem resistance rate of up to 12% in the US.⁷⁶ An epidemiological analysis in 2015 involving 50 countries showed that the international resistance rates of *P. aeruginosa* to carbapenems vary from 10% wide range to 60%.⁷⁷ Numerous resistance mechanisms drive the emergence of CRPA, most often including porin deficiency (especially OprD), efflux pump overactivity (mainly MexAB-OprM and MexCD-OprJ), and, less frequently, carbapenem-inactivating enzymes.⁷⁸

In a pediatric ICU, the rate of CRPA among VAP samples was 52%, and risk factors for the infection included length of stay until the diagnosis of VAP, presence of central venous catheters, prior use of cefepime, ciprofloxacin, colistin, and teicoplanin.⁷⁹ Furthermore, in a study of VAP in the ICU of three hospital centers in 2020, CRPA isolates showed high resistance for both imipenem and meropenem, with respectively 74% and 68%, and were most likely to exhibit upregulation of efflux pumps or porin loss.⁸⁰

Carbapenem-resistant *Enterobacteriales* (CRE)

The *Enterobacteriales* are frequently isolated in clinical cultures and are typical inhabitants of the digestive system in both humans and animals. Globally, the threat posed by CRE to human health is on the rise, imposing an urgent antimicrobial resistance threat. When opposed to strains that are carbapenem-susceptible, CRE frequently have numerous resistance genes that restrict treatment options, entail longer treatment durations, impose higher costs, and require therapies with higher toxicities.⁸¹ In fact, *Enterobacteriales* can become resistant to carbapenems by three possible mechanisms: efflux pump overactivity, outer membrane porin loss or mutation, and carbapenemase production, which remains the major resistance mechanism.⁸² Efflux pumps belonging to the resistance-nodulation-division (RND) are reported to contribute

to carbapenem resistance, such as the common AcrAB-TolC RND system.⁸³ Furthermore, reduced carbapenem susceptibility in *Enterobacterales* may result from reduced expression of outer membrane porins such as OmpF and OmpC, which mediate drug permeability.⁸⁴ However, carbapenemases remain the key determinants of resistance in CRE and they belong to different Ambler classes: Class A like KPC, Class B like NDM, IMP and VIM, and class D like OXA enzymes.⁵⁷ Noteworthy, CRE with high efflux activity or permeability defects may express any of these mechanisms paired to production of other β -lactamases such as AmpC cephalosporinases or extended-spectrum β -lactamases (ESBLs), indicating the heterogeneity of mechanisms driving the development of carbapenem resistance.⁸⁵

In pneumonia, antibiotic resistance profiles of *Enterobacterales* have gradually changed, indicating that close monitoring of those pathogens is fundamental for preventing further rise of resistance, development of treatment guidelines, and improving clinical therapy. For example, in China, an analysis of CRE in HAP over one decade showed an increase in the prevalence of these organisms from 0.8% to 11.6%.⁸⁶ In 2021, a prospective cohort study involving 5 tertiary referral centers in Korea detected 4% prevalence of CRE in HAP and 1% in VAP.⁸⁷ In another investigation, both carbapenem-resistant *K. pneumoniae* encoding OXA-48, and carbapenem-resistant *Enterobacter cloacae* encoding VIM-1, were identified in VAP, among a diverse group of β -lactamases.⁸⁰

Colistin-resistant Gram-negative bacteria

A cationic, polypeptide antibiotic, bactericidal against Gram-negative bacteria, colistin (polymyxin E)⁸⁸ has re-emerged as a possible antibiotic treatment option for MDR Gram-negative bacteria in HAP and VAP.⁸⁹ Its revival was prompted by its high effectiveness against MDR *A. baumannii*, *K. pneumoniae* and *P. aeruginosa*.⁹⁰ Polymyxins target on the outer membrane of Gram-negative bacteria using electrostatic interactions that develop between the positively charged polymyxin molecule and the negatively charged phosphate group that forms part of the lipid A residue of the bacterial cell wall lipopolysaccharide (LPS). Upon binding to the LPS and phospholipids in the outer cell membrane, polymyxins competitively displace divalent cations from the phosphate groups of membrane lipids, destabilizing the outer cell membrane, and causing leakage of intracellular contents and cell death.⁹¹ Undesirably, the use of polymyxins among the few enduring useable options for the therapy of MDR Gram-negative pathogens has prompted bacterial resistance. Such resistance may be chromosomal and associated with the modifications of lipid A, or may be encoded on transposable elements, namely mobile colistin resistance (*mcr*) genes. A review of the mechanisms of Gram-negative bacterial resistance to polymyxin has been meticulously presented elsewhere.⁸⁸

With the increase in the magnitude of resistance towards colistin among Gram-negative bacteria,⁹² reports of such resistance being an important drive of increased mortality are emerging.⁹³ In one survey, about 48% of *A. baumannii* isolated from patients with VAP in Greece, Italy, and Spain were colistin-resistant, with several amino acid substitutions in the PmrCAB two-component system.⁹⁴ With this system being responsible for addition of phosphoethanolamine to lipid A, its modifications reduce the net negative charge of the outer membrane, thereby affecting colistin binding and preventing loss of integrity and disruption of the cell membrane.⁹⁵ Likewise, in 2015, colistin-resistant *A. baumannii* isolates were identified at a hospital system in Pennsylvania from patients with VAP, with lipid A modification by the addition of phosphoethanolamine accounting for colistin resistance.⁹⁶

A prospective cohort research done in 2022 on MDR Gram-negative pathogens recovered from intubated patients with VAP showed colistin resistance rates of 3-20% among MDR *A. baumannii*, *K. pneumoniae*, as well as *P. aeruginosa*.⁹⁷ Also, in a 5-year retrospective study following over 5,500 patients in four general ICUs in Barcelona, Spain, the rate of colistin resistance among *P. aeruginosa* isolated from HAP or VAP specimens was 15%.⁹⁸ These numbers warrant careful attention to colistin use, and thorough re-evaluation of its introduction to antimicrobial therapy. According to an expert opinion published in 2021, the use of colistin in VAP has limited efficacy and significant nephrotoxicity.⁹⁹ The addition of the drug to the medication regimen did not show significant differences in patient mortality,⁹⁷ indicating that its use should rather be reassessed as newer agents become available, to prevent further buildup of colistin resistance among MDR Gram-negative pathogens.

Extended-spectrum β -lactamase (ESBL)-producing *Enterobacterales*

HAP and VAP due to ESBL-producing *Enterobacterales* represent also a growing problem. Indeed, ESBL producers are endemic in many countries, and 5 to 25% of ICU patients are carriers of these pathogens on admission. HAP and VAP caused by ESBL-producers are associated with a higher mortality than HAP and VAP due to susceptible *Enterobacterales* because the resistance profile decreases the adequacy rate of empiric therapy.¹⁰⁰ The spread of pathogens harboring ESBLs with concomitant resistance to carbapenems further complicates treatment outcomes.¹⁰¹ On molecular level, genes encoding carbapenem resistance, colistin resistance, and ESBLs are carried on highly mobile genetic elements, making them capable of easy transfer horizontally among bacteria with resulting additional dissemination and increase in resistance rates.¹⁰²

ESBL-producing *Enterobacterales* have been repeatedly described in HAP and VAP. In one study from Croatia, 4% of *K. pneumoniae* isolates and 2% of *E. cloacae* isolates were producers of ESBL, with group 1 CTX-M β -lactamases detected in patients with VAP.⁸⁰ In another report from France, ESBL-producing *Enterobacterales* accounted for 27% of VAP cases in a monocenter retrospective study among mechanically ventilated patients in the ICU.¹⁰³ Similar findings were reported in another study from Italy, where both carbapenemase-producing and ESBL-producing *K. pneumoniae* were identified in patients with VAP in the ICU.¹⁰⁴

MDR Gram-negative pathogens causing pneumonia in COVID-19 patients

The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious public health threat worldwide with different populations at risk.¹⁰⁵ The pandemic has resulted in millions of infections globally and has stressed both the healthcare and the economic systems to the extreme,¹⁰⁶ with over 650 million cases confirmed and a death toll reaching almost 7 million bereavements worldwide, as of November 2022.¹⁰⁷ Severe COVID-19 has sculpted critical challenges for research and medical communities, with older age, male sex, and comorbidities (hypertension, diabetes, cardiovascular disease, chronic pulmonary disease, chronic kidney disease, chronic liver disease, and cancer) being the common risks for severe disease. Given that SARS-CoV-2 viral entry is primarily through the respiratory tract, upper and lower respiratory tract involvement is the most common manifestation.¹⁰⁸ Observational studies report that COVID-19 patients suffer from secondary bacterial infections, worsening the disease and increasing mortality, particularly in those who require invasive mechanical ventilation. However, the rates of these bacterial co-infections and secondary infections remained low (5-7%),^{109,110} although critically sick ICU patients had higher rates.¹¹¹ Numerous studies of COVID-19 patients admitted to the ICU show that most patients were empirically administered antibiotics, increasing the prevalence of MDR pathogens.^{111,112} In general, the rates of VAP in patients with COVID-19 who were critically ill was reported to rise above 50%,¹¹³⁻¹¹⁷ with an estimated mortality exceeding 40%, and an increase in the number of patients requiring intensive care.¹¹⁸ In a multicenter study, VAP accounted for 50% of all hospital-acquired infections in patients with COVID-19, with 28% prevalence of Gram-negative pathogens as agents in VAP.¹¹⁹ In another case series, 2% of HAP and 33% of VAP were documented among COVID-19 patients admitted to the ICU, with VAP resulting in more acute respiratory distress syndrome (ARDS), and being associated with more acute kidney injury, long mechanical ventilation longer, and longer ICU stay.¹²⁰

Across studies of COVID-19 patients diagnosed with VAP, frequent growth of Gram-negative bacteria has been revealed in multiple studies, with predominantly high rates of *P. aeruginosa*.¹¹⁸ In 2022, Velázquez-García and Colleagues¹²¹ conducted a systematic review on causative agents of VAP and their antibiotic resistance patterns in COVID-19 patients and most collected studies were from France (32%), Italy (20%), Spain (12%), as well as the United States (8%). The prevalence of Gram-negative bacteria was highest in VAP, with ranges of 7.5-72.5% for *P. aeruginosa*, 6.9-43.7% for *K. pneumoniae*, 1.6-20% for *E. cloacae*, and 1.2-20% for *A. baumannii*. Likewise, a late systematic literature review summarizing available evidence regarding VAP in patients undergoing mechanical ventilation because of ARDS secondary to SARS-CoV-2 infection, reported Gram-negative bacteria to be the predominant microorganisms (>70% in most series) followed by Gram-positive bacteria (mostly *S. aureus*). Also, since most cases of COVID-19-related VAP are diagnosed more than 7 days from initiation of invasive mechanical ventilation, patients are at increased risk for MDR strains.¹²²

Only few studies investigated the susceptibility patterns among Gram-negative pathogens, and the main resistance mechanisms reported by these studies include the production by Gram-negative pathogens of ESBL, AmpC, and carbapenemases. Table 1 summarizes some findings of Gram-negative pathogens described in this review in patients with COVID-19-related VAP and remarkable data about their resistance. The published research revealed only limited

Table 1. Examples of VAP studies from COVID-19 patients and related Gram-negative pathogens, with a summary of resistance findings.

Country	Study setting/design	Gram-negative pathogens	Associated resistance type or mechanism	Reference
Italy	Multicenter, ICU	35% <i>Pseudomonas aeruginosa</i> 19% <i>Klebsiella pneumoniae</i>	32% of Gram-negative pathogens were carbapenem-resistant	123
Italy	Retrospective, observational in two ICUs of one hospital	<i>Pseudomonas</i> spp. accounted for 83% of VAP cases	84% of <i>Pseudomonas</i> spp. were carbapenem-resistant One out of 19 patients had co-infection with colistin resistant <i>Serratia marcescens</i>	124

Table 1. Continued

Country	Study setting/design	Gram-negative pathogens	Associated resistance type or mechanism	Reference
France	Retrospective, single-center in the ICU	Incidence of VAP due to MDR was significantly higher in COVID-19 patients (48%) versus non-COVID-19 patients (16%)	18% of VAP cases were caused by ESBL-producing <i>Enterobacteriales</i> , and 2% by CRE (including OXA-48 and NDM producing organisms)	103
France	Retrospective cohort study in a single ICU	<i>Enterobacteriales</i> accounted for 70% of VAP cases <i>Pseudomonas aeruginosa</i> accounted for 37% of VAP cases	40% of <i>Enterobacteriales</i> were AmpC-cephalosporinase producers 6% of <i>Enterobacteriales</i> were AmpC-cephalosporinase producers	125
United States	Observational, single-center in the ICU	33% of VAP episodes were caused by MDR organisms including primarily <i>P. aeruginosa</i> and <i>Enterobacteriales</i>	Not specified	126
Switzerland	Cohort, single-center, prospective study among ICU patients	<i>P. aeruginosa</i> (46%) and <i>Enterobacteriales</i> (36%) comprised the two largest etiologic groups	50% of <i>P. aeruginosa</i> were carbapenem resistant	127
Spain	Retrospective, single center in the ICU	<i>P. aeruginosa</i> comprised 38% of the cases of VAP, and it was the third most frequent resistant organism after <i>S. aureus</i> and <i>Enterococcus faecium</i>	Not specified	128
Belgium	Retrospective, single-center in the ICU	44% <i>Klebsiella</i> spp. 18% <i>P. aeruginosa</i> 11% <i>Enterobacter</i> spp.	29% of agents causing VAP were ESBL-producing <i>Klebsiella</i> spp., and 5% were extensively drug-resistant <i>P. aeruginosa</i> producing VIM which confers resistance to all tested antibiotics except aztreonam	129
Egypt	Two university hospitals with COVID-19 patient admission	Gram-negative isolates were predominant (above 70%) 28.5% <i>K. pneumoniae</i> 16.6% <i>A. baumannii</i> 9.5% <i>Escherichia coli</i> 9.5% <i>P. aeruginosa</i> 4.7% <i>Enterobacter cloacae</i> Fungal infections, caused by <i>Candida</i> (12%), were all mixed with bacteria	NDM-1 was the most predominant antibiotic resistance gene (55%), followed by CTX-M (52%), then TEM (41%), KPC (34%) and SHV (7%)	130

VAP=Ventilator-Associated Pneumonia; ICU=Intensive Care Unit; MDR=Multidrug-resistant; ESBL=Extended-Spectrum β -Lactamase; CRE=Carbapenem-Resistant *Enterobacteriales*.

information on the patterns of antibiotic resistance, as well as scarce data from low- and middle-income countries. As such, every effort should be implemented for monitoring and preventing these infections in the light of COVID-19 and bacterial resistance, and for provoking health systems preparedness for future pandemics.

Conclusions

With the above data, it is evident that the advent of Gram-negative pathogens with important antimicrobial resistance profiles has mounted with time in HAP and VAP, hindering treatment and adversely affecting clinical outcomes. Moreover, the increased recognition of these pathogens in patients with COVID-19 backs up recent distresses regarding the emergence of MDR bacterial co-infections during the global pandemic. As such, the development of approaches for alleviating the effect of these infections in this patient population should be a compulsory element of management tactics for COVID-19 patients, and part of the alertness for future outbreaks. It is evident that the dwindling antibiotic pipeline, and the major decline in the approval of new antibiotics or new classes, are exerting precarious pressure on demanding

infections like HAP and VAP. As such, more research, more funding, and more focus into advanced surveillance methods like whole genome sequencing, and innovative methods of antibiotic discovery like deep learning and artificial intelligence to address MDR Gram-negative pathogens, will ultimately influence the presentation of HAP and VAP, as well as other threatening infections.

Data availability

No data are associated with this article.

Acknowledgements

The authors would like to acknowledge Laveena Ramesh, for her technical assistance in preparation of [Figure 1](#).

References

- Grief SN, Loza JK: **Guidelines for the Evaluation and Treatment of Pneumonia.** *Prim. Care.* 2018 Sep; **45**(3): 485–503.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Gu CH, Lucero DE, Huang CC, et al.: **Pneumonia-Associated Hospitalizations, New York City, 2001-2014.** *Public Health Rep.* 2018; **133**(5): 584–592.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Shi T, Denouel A, Tietjen AK, et al.: **Global and Regional Burden of Hospital Admissions for Pneumonia in Older Adults: A Systematic Review and Meta-Analysis.** *J. Infect. Dis.* 2020 Oct 7; **222**(Supplement_7): S570–S576.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kaysin A, Viera AJ: **Community-Acquired Pneumonia in Adults: Diagnosis and Management.** *Am. Fam. Physician.* 2016 Nov 1; **94**(9): 698–706.
[PubMed Abstract](#)
- Torio CM, Moore BJ: **National inpatient hospital costs: the most expensive conditions by payer, 2013: statistical brief #204.** *Agency for Healthcare Research and Quality.* [cited 2016 May].
[Reference Source](#)
- Jain S, Self WH, Wunderink RG, et al.: **Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.** *N. Engl. J. Med.* 2015 Jul 30; **373**(5): 415–427.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Brenner NR, Shorr AF: **The evolving burden of viruses in pneumonia.** *Curr. Opin. Infect. Dis.* 2019 Apr; **32**(2): 158–162.
[Publisher Full Text](#)
- Cesario TC: **Viruses Associated With Pneumonia in Adults.** *Clin. Infect. Dis.* 2012 Jul 1; **55**(1): 107–113.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Assefa M: **Multi-drug resistant gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns.** *Pneumonia (Nathan).* 2022 May 5; **14**(1): 4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kalil AC, Metersky ML, Klompas M, et al.: **Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.** *Clin. Infect. Dis.* 2016 Sep 1; **63**(5): 575–582.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- American Thoracic Society, Infectious Diseases Society of America: **Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.** *Am. J. Respir. Crit. Care Med.* 2005 Feb 15; **171**(4): 388–416.
[Publisher Full Text](#)
- Ewig S, Welte T, Torres A: **Is healthcare-associated pneumonia a distinct entity needing specific therapy?** *Curr. Opin. Infect. Dis.* 2012 Apr; **25**(2): 166–175.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Yap V, Datta D, Metersky ML: **Is the present definition of health care-associated pneumonia the best way to define risk of infection with antibiotic-resistant pathogens?** *Infect. Dis. Clin. N. Am.* 2013 Mar; **27**(1): 1–18.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Chalmers JD, Rother C, Salih W, et al.: **Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis.** *Clin. Infect. Dis.* 2014 Feb; **58**(3): 330–339.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Torres A, Niederman MS, Chastre J, et al.: **International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT).** *Eur. Respir. J.* 2017 Sep; **50**(3): 1700582.
[Publisher Full Text](#)
- Kalil AC, Metersky ML, Klompas M, et al.: **Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.** *Clin. Infect. Dis.* 2016 Sep 1; **63**(5): e61–e111.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Luyt CE, Hékimian G, Koulenti D, et al.: **Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia.** *Curr. Opin. Crit. Care.* 2018 Oct; **24**(5): 332–338.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Modi AR, Kovacs CS: **Hospital-acquired and ventilator-associated pneumonia: Diagnosis, management, and prevention.** *Cleve. Clin. J. Med.* 2020 Oct 1; **87**(10): 633–639.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bassetti M, Mularoni A, Giacobbe DR, et al.: **New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia.** *Semin. Respir. Crit. Care Med.* 2022 Apr; **43**(2): 280–294.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Klompas M: **Hospital-Acquired Pneumonia in Nonventilated Patients: The Next Frontier.** *Infect. Control Hosp. Epidemiol.* 2016 Jul; **37**(7): 825–826.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ding C, Zhang Y, Yang Z, et al.: **Incidence, temporal trend and factors associated with ventilator-associated pneumonia in mainland China: a systematic review and meta-analysis.** *BMC Infect. Dis.* 2017 Jul 4; **17**: 468.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ścisło L, Walewska E, Bodys-Cupak I, et al.: **Nutritional Status Disorders and Selected Risk Factors of Ventilator-Associated Pneumonia (VAP) in Patients Treated in the Intensive Care Ward-A Retrospective Study.** *Int. J. Environ. Res. Public Health.* 2022 Jan 5; **19**(1): 602.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Jiménez-Trujillo I, Jiménez-García R, de Miguel-Díez J, et al.: **Incidence, characteristic and outcomes of ventilator-associated pneumonia among type 2 diabetes patients: An observational population-based study in Spain.** *Eur. J. Intern. Med.* 2017 May; **40**: 72–78.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hortal J, Giannella M, Pérez MJ, et al.: **Incidence and risk factors for ventilator-associated pneumonia after major heart surgery.** *Intensive Care Med.* 2009 Sep; **35**(9): 1518–1525.
[PubMed Abstract](#) | [Publisher Full Text](#)

25. Walaszek M, Kosiarska A, Gniadek A, *et al.*: **The risk factors for hospital-acquired pneumonia in the Intensive Care Unit.** *Przegł. Epidemiol.* 2016; **70**(1): 15–20, 107–10.
26. Sopena N, Heras E, Casas I, *et al.*: **Risk factors for hospital-acquired pneumonia outside the intensive care unit: a case-control study.** *Am. J. Infect. Control.* 2014 Jan; **42**(1): 38–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Charles MP, Kali A, Easow JM, *et al.*: **Ventilator-associated pneumonia.** *Australas Med. J.* 2014; **7**(8): 334–344.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Huang J, Cao Y, Liao C, *et al.*: **Effect of histamine-2-receptor antagonists versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients: a meta-analysis of 10 randomized controlled trials.** *Crit. Care.* 2010; **14**(5): R194.
[Publisher Full Text](#)
29. Huang HB, Jiang W, Wang CY, *et al.*: **Stress ulcer prophylaxis in intensive care unit patients receiving enteral nutrition: a systematic review and meta-analysis.** *Crit. Care.* 2018 Jan 28; **22**(1): 20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Magill SS, O'Leary E, Janelle SJ, *et al.*: **Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals.** *N. Engl. J. Med.* 2018 Nov 1; **379**(18): 1732–1744.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Pássaro L, Harbarth S, Landelle C: **Prevention of hospital-acquired pneumonia in non-ventilated adult patients: a narrative review.** *Antimicrob. Resist. Infect. Control.* 2016; **5**: 43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Sangmuang P, Lucksiri A, Katip W: **Factors Associated with Mortality in Immunocompetent Patients with Hospital-acquired Pneumonia.** *J. Global Infect. Dis.* 2019; **11**(1): 13–18.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Nusrat T, Akter N, Rahman NAA, *et al.*: **Antibiotic resistance and sensitivity pattern of Metallo- β -Lactamase Producing Gram-Negative Bacilli in ventilator-associated pneumonia in the intensive care unit of a public medical school hospital in Bangladesh.** *Hosp. Pract (1995).* 2020 Aug; **48**(3): 128–136.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Wang Y, Eldridge N, Metersky ML, *et al.*: **National trends in patient safety for four common conditions, 2005–2011.** *N. Engl. J. Med.* 2014 Jan 23; **370**(4): 341–351.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Melsen WG, Rovers MM, Groenwold RHH, *et al.*: **Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies.** *Lancet Infect. Dis.* 2013 Aug; **13**(8): 665–671.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Torres A, Cilloniz C, Niederman MS, *et al.*: **Pneumonia.** *Nat. Rev. Dis. Primers.* 2021 Apr 8; **7**(1): 25.
[Publisher Full Text](#)
37. Ibn Saïed W, Mourvillier B, Cohen Y, *et al.*: **A Comparison of the Mortality Risk Associated With Ventilator-Acquired Bacterial Pneumonia and Nonventilator ICU-Acquired Bacterial Pneumonia.** *Crit. Care Med.* 2019 Mar; **47**(3): 345–352.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Weiss E, Essaïed W, Adrie C, *et al.*: **Treatment of severe hospital-acquired and ventilator-associated pneumonia: a systematic review of inclusion and judgment criteria used in randomized controlled trials.** *Crit. Care.* 2017 Jun 27; **21**(1): 162.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Dananché C, Vanhems P, Machut A, *et al.*: **Trends of Incidence and Risk Factors of Ventilator-Associated Pneumonia in Elderly Patients Admitted to French ICUs Between 2007 and 2014.** *Crit. Care Med.* 2018 Jun; **46**(6): 869–877.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Enne VI, Personne Y, Grgic L, *et al.*: **Aetiology of hospital-acquired pneumonia and trends in antimicrobial resistance.** *Curr. Opin. Pulm. Med.* 2014 May; **20**(3): 252–258.
[Publisher Full Text](#)
41. Weiner LM, Webb AK, Limbago B, *et al.*: **Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014.** *Infect. Control Hosp. Epidemiol.* 2016 Nov; **37**(11): 1288–1301.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Jean SS, Chang YC, Lin WC, *et al.*: **Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia.** *J. Clin. Med.* 2020 Jan 19; **9**(1): E275.
[Publisher Full Text](#)
43. Cerceo E, Deitelzweig SB, Sherman BM, *et al.*: **Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options.** *Microb. Drug Resist.* 2016 Jul; **22**(5): 412–431.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Bonell A, Azarrافی R, Huong VTL, *et al.*: **A Systematic Review and Meta-analysis of Ventilator-associated Pneumonia in Adults in Asia: An Analysis of National Income Level on Incidence and Etiology.** *Clin. Infect. Dis.* 2019 Jan 18; **68**(3): 511–518.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Kharel S, Bist A, Mishra SK: **Ventilator-associated pneumonia among ICU patients in WHO Southeast Asian region: A systematic review.** *PLoS One.* 2021; **16**(3): e0247832.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Koulenti D, Lisboa T, Brun-Buisson C, *et al.*: **Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units.** *Crit. Care Med.* 2009 Aug; **37**(8): 2360–2369.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Koulenti D, Tsigou E, Rello J: **Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study.** *Eur. J. Clin. Microbiol. Infect. Dis.* 2017 Nov; **36**(11): 1999–2006.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Guzek A, Korzeniewski K, Tomaszewski D, *et al.*: **Bacteriological Assessment of Pneumonia Caused by Gram-Negative Bacteria in Patients Hospitalized in Intensive Care Unit.** *Adv. Exp. Med. Biol.* 2017; **955**: 39–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Djordjevic ZM, Folic MM, Jankovic SM: **Distribution and antibiotic susceptibility of pathogens isolated from adults with hospital-acquired and ventilator-associated pneumonia in intensive care unit.** *J. Infect. Public Health.* 2017 Nov 1; **10**(6): 740–744.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Kanafani ZA, El Zakhem A, Zahreddine N, *et al.*: **Ten-year surveillance study of ventilator-associated pneumonia at a tertiary care center in Lebanon.** *J. Infect. Public Health.* 2019 Aug; **12**(4): 492–495.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. El-Saed A, Balkhy HH, Al-Dorzi HM, *et al.*: **Acinetobacter is the most common pathogen associated with late-onset and recurrent ventilator-associated pneumonia in an adult intensive care unit in Saudi Arabia.** *Int. J. Infect. Dis.* 2013 Sep; **17**(9): e696–e701.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Rahman M, Hashmey R, Abuhasna S: **Ventilator Associated Pneumonia: A 22-Month Prospective Observational Study from a Tertiary Care Centre in United Arab Emirates.** *Int. J. Infect. Dis.* 2008 Dec 1; **12**: e370–e371.
[Publisher Full Text](#)
53. Jones RN: **Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.** *Clin. Infect. Dis.* 2010 Aug 1; **51** Suppl 1: S81–S87.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Behnia M, Logan SC, Fallen L, *et al.*: **Nosocomial and ventilator-associated pneumonia in a community hospital intensive care unit: a retrospective review and analysis.** *BMC. Res. Notes.* 2014 Apr 11; **7**: 232.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
55. Tacconelli E, Carrara E, Savoldi A, *et al.*: **Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.** *Lancet Infect. Dis.* 2018 Mar; **18**(3): 318–327.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Ayoub Moubareck C, Hammoudi HD: **Insights into Acinetobacter baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen.** *Antibiotics (Basel).* 2020 Mar 12; **9**(3).
[Publisher Full Text](#)
57. Hammoudi Halat D, Ayoub MC: **The Current Burden of Carbapenemases: Review of Significant Properties and Dissemination among Gram-Negative Bacteria.** *Antibiotics (Basel).* 2020 Apr 16; **9**(4): E186.
[Publisher Full Text](#)
58. Moubareck C, Brémont S, Conroy MC, *et al.*: **GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.** *Antimicrob. Agents Chemother.* 2009 Aug; **53**(8): 3579–3581.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. López-Hernández S, Alarcón T, López-Brea M: **Carbapenem resistance mediated by beta-lactamases in clinical isolates of Acinetobacter baumannii in Spain.** *Eur. J. Clin. Microbiol. Infect. Dis.* 1998 Apr; **17**(4): 282–285.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Chaari A, Mnif B, Bahloul M, *et al.*: **Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors.** *Int. J. Infect. Dis.* 2013 Dec 1; **17**(12): e1225–e1228.
[PubMed Abstract](#) | [Publisher Full Text](#)

61. Özgür ES, Horasan ES, Karaca K, *et al.*: Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: risk factors, clinical features, and outcomes. *Am. J. Infect. Control.* 2014 Feb; **42**(2): 206–208. [PubMed Abstract](#) | [Publisher Full Text](#)
62. Inchai J, Liwsrisakun C, Theerakittikul T, *et al.*: Risk factors of multidrug-resistant, extensively drug-resistant and pandrug-resistant Acinetobacter baumannii ventilator-associated pneumonia in a Medical Intensive Care Unit of University Hospital in Thailand. *J. Infect. Chemother.* 2015 Aug; **21**(8): 570–574. [PubMed Abstract](#) | [Publisher Full Text](#)
63. Chittawatanarat K, Jaipakdee W, Chotirosniramit N, *et al.*: Microbiology, resistance patterns, and risk factors of mortality in ventilator-associated bacterial pneumonia in a Northern Thai tertiary-care university based general surgical intensive care unit. *Infect. Drug Resist.* 2014 Aug 16; **7**: 203–210. [PubMed Abstract](#) | [Publisher Full Text](#)
64. Čiginskienė A, Dambrauskienė A, Rello J, *et al.*: Ventilator-Associated Pneumonia due to Drug-Resistant Acinetobacter baumannii: Risk Factors and Mortality Relation with Resistance Profiles, and Independent Predictors of In-Hospital Mortality. *Medicina (Kaunas).* 2019 Feb 13; **55**(2): E49. [Publisher Full Text](#)
65. Inchai J, Pothirat C, Bumroongkit C, *et al.*: Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia. *J. Intensive Care.* 2015; **3**: 9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
66. Salehi M, Jafari S, Ghafouri L, *et al.*: Ventilator-associated Pneumonia: Multidrug Resistant Acinetobacter vs. Extended Spectrum Beta Lactamase-producing Klebsiella. *J. Infect. Dev. Ctries.* 2020 Jun 30; **14**(6): 660–663. [PubMed Abstract](#) | [Publisher Full Text](#)
67. Carneiro M, Barbosa PIPL, Vespero EC, *et al.*: Carbapenem-resistant OXA-23-producing Acinetobacter baumannii isolates causing ventilator-associated pneumonia. *Am. J. Infect. Control.* 2010 Oct; **38**(8): 667–669. [PubMed Abstract](#) | [Publisher Full Text](#)
68. Royer S, Faria ALS, Seki LM, *et al.*: Spread of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clones in patients with ventilator-associated pneumonia in an adult intensive care unit at a university hospital. *Braz. J. Infect. Dis.* 2015 Aug; **19**(4): 350–357. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. Ishtiaq S, Saleem S, Waheed A, *et al.*: Molecular detection of blaOXA-23 gene and blaOXA-51 gene in carbapenem resistant strains of Acinetobacter baumannii in patients with ventilator associated pneumonia at tertiary care hospitals. *J. Pak. Med. Assoc.* 2021 Nov; **71**(11): 2576–2581. [Publisher Full Text](#)
70. Zhang T, Xu X, Xu CF, *et al.*: Mechanical ventilation-associated pneumonia caused by Acinetobacter baumannii in Northeast China region: analysis of genotype and drug resistance of bacteria and patients' clinical features over 7 years. *Antimicrob. Resist. Infect. Control.* 2021 Sep 15; **10**(1): 135. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. Xia J, Zhang D, Xu Y, *et al.*: A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam. *Int. J. Infect. Dis.* 2014 Jun; **23**: 90–93. [PubMed Abstract](#) | [Publisher Full Text](#)
72. Mohammadi M, Soroush S, Delfani S, *et al.*: Distribution of Class D Carbapenemase and Extended-Spectrum β -Lactamase Genes among Acinetobacter Baumannii Isolated from Burn Wound and Ventilator Associated Pneumonia Infections. *J. Clin. Diagn. Res.* 2017 Jul; **11**(7): DC19–DC23. [PubMed Abstract](#) | [Publisher Full Text](#)
73. Hoang Quoc C, Nguyen Thi Phuong T, Nguyen Duc H, *et al.*: Carbapenemase Genes and Multidrug Resistance of Acinetobacter Baumannii: A Cross Sectional Study of Patients with Pneumonia in Southern Vietnam. *Antibiotics (Basel).* 2019 Sep 12; **8**(3): E148. [Publisher Full Text](#)
74. Nowak J, Zander E, Stefanik D, *et al.*: High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. *J. Antimicrob. Chemother.* 2017 Dec 1; **72**(12): 3277–3282. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. Jurado-Martin I, Sainz-Mejias M, McClean S: Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. *Int. J. Mol. Sci.* 2021 Mar 18; **22**(6): 3128. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
76. Walters MS, Grass JE, Bulens SN, *et al.*: Carbapenem-Resistant Pseudomonas aeruginosa at US Emerging Infections Program Sites, 2015. *Emerg. Infect. Dis.* 2019 Jul; **25**(7): 1281–1288. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
77. Hong DJ, Bae IK, Jang IH, *et al.*: Epidemiology and Characteristics of Metallo- β -Lactamase-Producing Pseudomonas aeruginosa. *Infect. Chemother.* 2015 Jun; **47**(2): 81–97. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
78. Eichenberger EM, Thaden JT: Epidemiology and Mechanisms of Resistance of Extensively Drug Resistant Gram-Negative Bacteria. *Antibiotics (Basel).* 2019 Apr 6; **8**(2): E37. [Publisher Full Text](#)
79. Kara SS, Polat M, Tapisiz A, *et al.*: Ventilator associated pneumonia due to carbapenem resistant microorganisms in children. *Minerva Pediatr.* 2019 Aug; **71**(4): 349–357. [PubMed Abstract](#) | [Publisher Full Text](#)
80. Bandić-Pavlović D, Zah-Bogović T, Žižek M, *et al.*: Gram-negative bacteria as causative agents of ventilator-associated pneumonia and their respective resistance mechanisms. *J. Chemother.* 2020 Nov; **32**(7): 344–358. [PubMed Abstract](#) | [Publisher Full Text](#)
81. Tompkins K, van Duin D: Treatment for carbapenem-resistant Enterobacteriales infections: recent advances and future directions. *Eur. J. Clin. Microbiol. Infect. Dis.* 2021 Oct; **40**(10): 2053–2068. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
82. Nordmann P: Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. *Med. Mal. Infect.* 2014 Feb; **44**(2): 51–56. [PubMed Abstract](#) | [Publisher Full Text](#)
83. Li XZ, Plésiat P, Nikaido H: The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. *Clin. Microbiol. Rev.* 2015 Apr; **28**(2): 337–418. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
84. Tängdén T, Adler M, Cars O, *et al.*: Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model. *J. Antimicrob. Chemother.* 2013 Jun; **68**(6): 1319–1326. [PubMed Abstract](#) | [Publisher Full Text](#)
85. Shropshire WC, Konovalova A, McDanel D, *et al.*: Systematic Analysis of Mobile Genetic Elements Mediating β -Lactamase Gene Amplification in Noncarbapenemase-Producing Carbapenem-Resistant Enterobacteriales Bloodstream Infections. *mSystems.* 2022 Oct 26; **7**(5): e0047622. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
86. Yin Y, Zhao C, Li H, *et al.*: Clinical and microbiological characteristics of adults with hospital-acquired pneumonia: a 10-year prospective observational study in China. *Eur. J. Clin. Microbiol. Infect. Dis.* 2021 Apr; **40**(4): 683–690. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
87. Chang Y, Jeon K, Lee SM, *et al.*: The Distribution of Multidrug-resistant Microorganisms and Treatment Status of Hospital-acquired Pneumonia/Ventilator-associated Pneumonia in Adult Intensive Care Units: a Prospective Cohort Observational Study. *J. Korean Med. Sci.* 2021 Oct 25; **36**(41): e251. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
88. Ayoub MC: Polymyxins and Bacterial Membranes: A Review of Antibacterial Activity and Mechanisms of Resistance. *Membranes (Basel).* 2020 Aug 8; **10**(8): E181. [Publisher Full Text](#)
89. Gu WJ, Wang F, Tang L, *et al.*: Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: a systematic review and meta-analysis. *Int. J. Antimicrob. Agents.* 2014 Dec; **44**(6): 477–485. [PubMed Abstract](#) | [Publisher Full Text](#)
90. Abdelsalam MFA, Abdalla MS, El-Abhar HSED: Prospective, comparative clinical study between high-dose colistin monotherapy and colistin-meropenem combination therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae. *J. Glob. Antimicrob. Resist.* 2018 Dec 1; **15**: 127–135. [PubMed Abstract](#) | [Publisher Full Text](#)
91. Evans ME, Feola DJ, Rapp RP: Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. *Ann. Pharmacother.* 1999 Sep; **33**(9): 960–967. [PubMed Abstract](#) | [Publisher Full Text](#)
92. Olaitan AO, Morand S, Rolain JM: Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. *Front. Microbiol.* 2014; **5**: 643.
93. Rojas LJ, Salim M, Cober E, *et al.*: Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality. *Clin. Infect. Dis.* 2017 Mar 15;

- 64(6): 711–718.
[PubMed Abstract](#) | [Publisher Full Text](#)
94. Gerson S, Lucaßen K, Wille J, *et al.*: **Diversity of amino acid substitutions in PmrCAB associated with colistin resistance in clinical isolates of Acinetobacter baumannii.** *Int. J. Antimicrob. Agents.* 2020 Mar; **55**(3): 105862.
[PubMed Abstract](#) | [Publisher Full Text](#)
95. Falagas ME, Kasiakou SK: **Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.** *Clin. Infect. Dis.* 2005 May 1; **40**(9): 1333–1341.
[PubMed Abstract](#) | [Publisher Full Text](#)
96. Qureshi ZA, Hittle LE, O'Hara JA, *et al.*: **Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.** *Clin. Infect. Dis.* 2015 May 1; **60**(9): 1295–1303.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
97. Vo TPM, Dinh TC, Phan HV, *et al.*: **Ventilator-Associated Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacteria in Vietnam: Antibiotic Resistance, Treatment Outcomes, and Colistin-Associated Adverse Effects.** *Healthcare (Basel).* 2022 Sep 14; **10**(9): 1765.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
98. Borgatta B, Gattarello S, Mazo CA, *et al.*: **The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs.** *Eur. J. Clin. Microbiol. Infect. Dis.* 2017 Nov; **36**(11): 2155–2163.
[PubMed Abstract](#) | [Publisher Full Text](#)
99. Mahmood SN, Shorr AF: **Issues in antibiotic therapy for hospital-acquired and ventilator-associated pneumonia: emerging concepts to improve outcomes.** *Expert. Opin. Pharmacother.* 2021 Aug; **22**(12): 1547–1553.
[PubMed Abstract](#) | [Publisher Full Text](#)
100. Timsit JF, Pilmis B, Zahar JR: **How Should We Treat Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae?** *Semin. Respir. Crit. Care Med.* 2017 Jun; **38**(3): 287–300.
[PubMed Abstract](#) | [Publisher Full Text](#)
101. Liu J, Du SX, Zhang JN, *et al.*: **Spreading of extended-spectrum β -lactamase-producing Escherichia coli ST131 and Klebsiella pneumoniae ST11 in patients with pneumonia: a molecular epidemiological study.** *Chin. Med. J.* 2019 Aug 20; **132**(16): 1894–1902.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
102. Oliveira J, Reygaert WC: **Gram Negative Bacteria.** *StatPearls.* Treasure Island (FL): StatPearls Publishing; 2021 [cited 2021 Oct 2].
[Reference Source](#)
103. Razazi K, Arrestier R, Haudebourg AF, *et al.*: **Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease.** *Crit. Care.* 2020 Dec 18; **24**: 699.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
104. Montrucchio G, Corcione S, Sales G, *et al.*: **Carbapenem-resistant Klebsiella pneumoniae in ICU-admitted COVID-19 patients: Keep an eye on the ball.** *J. Glob. Antimicrob. Resist.* 2020 Dec; **23**: 398–400.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
105. Majumder J, Minko T: **Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19.** *AAPS J.* 2021 Jan 5; **23**(1): 14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
106. Ochani R, Asad A, Yasmin F, *et al.*: **COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management.** *Infez. Med.* 2021 Mar 1; **29**(1): 20–36.
[PubMed Abstract](#)
107. WHO Coronavirus (COVID-19) Dashboard: [cited 2022 Nov 26].
[Reference Source](#)
108. Attaway AH, Scheraga RG, Bhimraj A, *et al.*: **Severe covid-19 pneumonia: pathogenesis and clinical management.** *BMJ.* 2021 Mar 10; **372**: n436.
[Publisher Full Text](#)
109. Garcia-Vidal C, Sanjuan G, Moreno-García E, *et al.*: **Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study.** *Clin. Microbiol. Infect.* 2021 Jan; **27**(1): 83–88.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
110. Baskaran V, Lawrence H, Lansbury LE, *et al.*: **Co-infection in critically ill patients with COVID-19: an observational cohort study from England.** *J. Med. Microbiol.* 2021 Apr; **70**(4): 001350.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
111. Pourajam S, Kalantari E, Talebzadeh H, *et al.*: **Secondary Bacterial Infection and Clinical Characteristics in Patients With COVID-19 Admitted to Two Intensive Care Units of an Academic Hospital in Iran During the First Wave of the Pandemic.** *Front. Cell. Infect. Microbiol.* 2022; **12**: 784130.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
112. Lingas EC: **Empiric Antibiotics in COVID 19: A Narrative Review.** *Cureus.* 2022 Jun; **14**(6): e25596.
[PubMed Abstract](#) | [Publisher Full Text](#)
113. Maes M, Higginson E, Pereira-Dias J, *et al.*: **Ventilator-associated pneumonia in critically ill patients with COVID-19.** *Crit. Care.* 2021 Jan 11; **25**: 25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
114. Rouzé A, Martin-Loeches I, Povoá P, *et al.*: **Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study.** *Intensive Care Med.* 2021 Feb; **47**(2): 188–198.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
115. Rouzé A, Saura O, Nseir S: **High Incidence of Nosocomial Infections in COVID-19 Patients.** *Chest.* 2021 Sep; **160**(3): e315.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
116. Vacheron CH, Lepape A, Savey A, *et al.*: **Increased Incidence of Ventilator-Acquired Pneumonia in Coronavirus Disease 2019 Patients: A Multicentric Cohort Study.** *Crit. Care Med.* 2022 Mar 1; **50**(3): 449–459.
[PubMed Abstract](#) | [Publisher Full Text](#)
117. Szarpak L, Wisco J, Boyer R: **How healthcare must respond to ventilator-associated pneumonia (VAP) in invasively mechanically ventilated COVID-19 patients.** *Am. J. Emerg. Med.* 2021 Oct; **48**: 361–362.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
118. Boyd S, Nseir S, Rodriguez A, *et al.*: **Ventilator-associated pneumonia in critically ill patients with COVID-19 infection: a narrative review.** *ERJ Open Res.* 2022 Jul; **8**(3): 00046–02022.
[Publisher Full Text](#)
119. Grasselli G, Scaravilli V, Mangioni D, *et al.*: **Hospital-Acquired Infections in Critically Ill Patients With COVID-19.** *Chest.* 2021 Aug; **160**(2): 454–465.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
120. Dudoignon E, Caméléna F, Deniau B, *et al.*: **Bacterial Pneumonia in COVID-19 Critically Ill Patients: A Case Series.** *Clin. Infect. Dis.* 2020 Jun 16; **72**: 905–906.
[Publisher Full Text](#)
121. Velásquez-García L, Mejía-Sanjuanelo A, Viasus D, *et al.*: **Causative Agents of Ventilator-Associated Pneumonia and Resistance to Antibiotics in COVID-19 Patients: A Systematic Review.** *Biomedicines.* 2022 May 24; **10**(6): 1226.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
122. Fumagalli J, Panigada M, Klompas M, *et al.*: **Ventilator-associated pneumonia among SARS-CoV-2 acute respiratory distress syndrome patients.** *Curr. Opin. Crit. Care.* 2022 Feb 1; **28**(1): 74–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
123. Giacobbe DR, Battaglini D, Enrile EM, *et al.*: **Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study.** *J. Clin. Med.* 2021 Feb 3; **10**(4): 555.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
124. Burastero GJ, Orlando G, Santoro A, *et al.*: **Ceftazidime/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature.** *Antibiotics (Basel).* 2022 Jul 26; **11**(8): 1007.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
125. Luyt CE, Sahnoun T, Gautier M, *et al.*: **Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study.** *Ann. Intensive Care.* 2020 Nov 23; **10**: 158.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
126. Pickens CO, Gao CA, Cuttica MJ, *et al.*: **Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia.** *Am. J. Respir. Crit. Care Med.* 2020; **204**(8): 921–932.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
127. Gysin M, Acevedo CT, Haldimann K, *et al.*: **Antimicrobial susceptibility patterns of respiratory Gram-negative bacterial isolates from COVID-19 patients in Switzerland.** *Ann. Clin. Microbiol. Antimicrob.* 2021 Sep 7; **20**(1): 64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
128. Bardi T, Pintado V, Gomez-Rojo M, *et al.*: **Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome.** *Eur. J. Clin. Microbiol. Infect. Dis.* 2021; **40**(3): 495–502.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
129. Moretti M, Van Laethem J, Minini A, *et al.*: **Ventilator-associated bacterial pneumonia in coronavirus 2019 disease, a retrospective monocentric cohort study.** *J. Infect. Chemother.*

2021 Jun; **27**(6): 826–833.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

130. Ramadan HKA, Mahmoud MA, Aburahma MZ, *et al.*: **Predictors of Severity and Co-Infection Resistance Profile in COVID-19**

Patients: First Report from Upper Egypt. *Infect. Drug Resist.* 2020; **13**: 3409–3422.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status: ?

Version 1

Reviewer Report 24 April 2023

<https://doi.org/10.5256/f1000research.141737.r163960>

© 2023 Dbaibo G. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Ghassan Dbaibo

Center for Infectious Diseases Research, Division of Pediatric Infectious Diseases, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon

This is an excellent current review of the topic of hospital-acquired pneumonia and ventilator-associated pneumonia in the setting of increasing resistance among the responsible Gram-negative organisms.

1. There are some missing references.
2. There are some problems with grammar, spelling, and syntax that could be improved
3. Title maybe a bit misleading "Bacterial Pneumonia" since the focus is on HAP and VAP.
4. Methodology is absent. Perhaps a statement indicating how the authors decided to perform this review would be appropriate. How did they choose the references in this review, including some but not others? What questions were they looking to answer? If this is a descriptive review, what is the scope (geography, age, setting, time-frame, etc.)?
5. It may have made more sense to start with ESBL Enterobacterales since they emerged first, among the categories highlighted, followed by the others (instead of starting with carbapenem-resistant organisms).
6. Page 4, third paragraph (of the pdf version of the article): "Evidence indicates....", this statement requires at least one, preferably more references.
7. Page 4, third paragraph: "Pneumonia etiology is thought...", this should be HAP etiology, as overall pneumonia is still dominated by *S. pneumoniae*.
8. Page 4, last paragraph: "Parallel results were reported...", do the authors mean "Similar results were...."?
9. Throughout: full bacterial name only needed with first mention, subsequently abbreviation

can be used, e.g. *S. maltophilia* (misspelled on at least one occasion)

10. Page 6, first paragraph: parentheses not closed (*bla...*)
11. Throughout: The resistance enzymes should be presented consistently, e.g. *bla*_{OXA} versus OXA
12. Page 6, second paragraph, line 7: "wide range" seems to be misplaced between the lower and upper limit
13. Page 6, third paragraph, line 3: "opposed" should be replaced by "compared", it reads better

Is the topic of the review discussed comprehensively in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Partly

Is the review written in accessible language?

Partly

Are the conclusions drawn appropriate in the context of the current research literature?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Infectious diseases and sphingolipid biochemistry

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research